StocksMedium•4 November 2026•
1 min read
OPKO Health Reports Q3 2026 Results and Agrees to Sell Diagnostic Assets to Labcorp
Key Facts
1OPKO Health reported its third-quarter 2026 financial results and business highlights.
2OPKO Health entered into an agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations.
OPKO Health reported its third-quarter 2026 financial results and business highlights, according to a statement released via GlobeNewswire. The company entered into an agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations as part of a strategy to focus on its core biopharmaceutical business.
OPK stock closed at $1.72 on November 3, 2026, while LH, the ticker for Labcorp, closed at $353.92 on the same date. The divestiture follows the OPKO Health Board of Directors' approval on September 30, 2026, of a plan to sell the diagnostic operations, leading the company to classify the assets as held for sale.